Artis BioSolutions, a company founded to streamline the discovery, development and production of genetic medicines, announced its launch, alongside its acquisition of Landmark Bio. Landmark Bio is a cell and gene therapy manufacturing company specializing in translational research, process development, and manufacturing technologies. With the acquisition of Landmark Bio, Artis BioSolutions is well-positioned as a premiere CDMO for advanced therapy developers looking for end-to-end capabilities within the underserved and fast-growing category of advanced therapies. Initial funding for Artis is provided by Oak HC/FT.
Read the full article: Artis BioSolutions Emerges from Stealth, Announces Acquisition of Landmark Bio //
Source: https://www.businesswire.com/news/home/20250402597301/en/Artis-BioSolutions-Emerges-from-Stealth-Announces-Acquisition-of-Landmark-Bio